Skip to content

Released Aug 10, 2023, before the open

10-Q filed Aug 10, 2023, 41 days after period end · 0001785530-23-000025

Q2 2023 · 10-Q
Revenue—
Net Income-$5.10MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.14N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$6,067,000N/M
Operating Cash Flowderived-$10,921,000N/M
Free Cash Flowderived-$11,103,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Net Income-$5.10M-$14.59M-$10.92M$2.26M
EPS Diluted-$0.14-$0.53-$3.82$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR